What is the pharmacokinetic difference between the four esters in Suste-Testosterone 400mg?

Each ester has a distinct carbon-chain length that determines how quickly plasma esterases cleave it: propionate activates within 24–48 hours, phenylpropionate peaks around days 2–5, isocaproate sustains activity through day 8–12, and decanoate provides a residual androgenic baseline up to 18–21 days post-injection. Together they create a seamless release cascade that no single ester can replicate alone.

How does injectable testosterone ester delivery compare to oral or transdermal forms?

Injectable esterified testosterone achieves near-complete systemic bioavailability because the intramuscular depot bypasses hepatic first-pass metabolism entirely. Transdermal testosterone delivers only 10–15% of the applied dose to systemic circulation according to published pharmacokinetic data. Oral testosterone variants require 17-alpha-alkylation for absorption, which introduces hepatotoxic liability that esterified injectables like Suste-Testosterone 400mg do not carry.

Which ester fraction within Suste-Testosterone 400mg is most useful for athletes who want rapid androgenic onset?

The propionate fraction is responsible for rapid onset — it is hydrolysed within the first 24–48 hours and generates the earliest measurable serum testosterone elevation. This makes the blend suitable for athletes who cannot tolerate the 5–7 day lag associated with long-ester-only products like testosterone enanthate or cypionate, while the remaining three esters maintain androgenic activity through the weeks that follow.

Why does Suste-Testosterone 400mg draw a smaller injection volume than 250mg/ml blends at the same weekly dose?

At 400mg/ml, each millilitre contains 60% more active testosterone esters than a 250mg/ml formulation. A 600mg weekly dose requires only 1.5ml of Suste-Testosterone 400mg versus 2.4ml of a 250mg/ml product — a 37.5% volume reduction per administration. Smaller oil depot volume per injection lowers depot pressure at the injection site, which users typically associate with reduced post-injection discomfort.

How should the 10ml vial of Suste-Testosterone 400mg be stored and handled after the first draw?

Store the vial at controlled room temperature (15–25°C), away from direct light and moisture. After the first needle puncture of the rubber septum, maintain aseptic technique — use a new sterile needle for every draw. The vial does not require refrigeration after opening, but should not be exposed to temperatures above 30°C. Inspect the solution visually before each draw; discard the vial if particulate matter or cloudiness is observed. (2) angle_used

Verified Manufacturer

Beligas Pharmaceuticals

Suste-Testosterone 400mg 400mg/ml 10ml Vial by Beligas Pharmaceuticals

Name: Suste-Testosterone 400mg 400mg/ml 10ml Vial by Beligas Pharmaceuticals
Brand: Beligas Pharmaceuticals
SKU: INJ-TMIX-BEL-400-003
Price: 48.00 EUR
Availability: InStock
Rating: 5 (2 reviews)

5 (2 reviews)

Suste-Testosterone 400mg is a high-concentration, oil-based injectable testosterone blend containing four distinct ester fractions — propionate, phenylpropionate, isocaproate, and decanoate — combined at 400mg/ml in a 10ml multi-dose vial, engineered to deliver a continuous androgenic release profile across a wide pharmacokinetic window. Each ester contributes a non-overlapping release phase: the shortest ester activates within 24 hours, while the decanoate component sustains serum testosterone for up to 18–21 days per injection cycle. Quality is locked in at two production stages — raw-material identity confirmed by HPLC against certified reference standards, and finished vials cleared by LAL endotoxin assay before lot release.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers an uninterrupted androgenic signal from day one through day 21 via a four-ester pharmacokinetic cascade
Reduces per-dose injection volume by approximately 37.5% compared to standard 250mg/ml multi-ester products at identical weekly testosterone doses
Bypasses hepatic first-pass metabolism entirely, achieving near-complete systemic bioavailability from the intramuscular oil depot
Each of the four ester fractions contributes a non-overlapping release phase, eliminating the lag period associated with long-ester-only formulations
10ml vial format at 400mg/ml consolidates 4,000mg of total testosterone esters into a single vessel — sufficient for a full 10-week cycle at 400mg/week
Lot-specific HPLC verification confirms individual ester proportions match declared specification, not only total testosterone concentration
Verified Manufacturer status from Beligas Pharmaceuticals with LAL endotoxin clearance on every finished lot before distribution

Phase	dosage	Note
Introductory / Ester Familiarisation	300–400mg/week (0.75–1.0ml)	Allows assessment of individual ester fraction tolerability; the propionate component activates within 24–48 hours confirming product activity early
Intermediate Bulking	400–600mg/week (1.0–1.5ml)	Twice-weekly split (e.g. Monday/Thursday) maintains overlap between the decanoate tail and the propionate rise of the next injection, stabilising serum testosterone
Advanced / High-Volume	600–800mg/week (1.5–2.0ml)	At 400mg/ml, 2.0ml per injection delivers 800mg — a dose achievable with half the oil volume required from a 250mg/ml formulation, reducing depot discomfort
TRT / Therapeutic Maintenance	100–200mg/week (0.25–0.5ml)	Lower-volume draw at 400mg/ml; insulin-calibrated 1ml syringes provide 0.025ml graduation increments (10mg per increment) for precise dose control
Taper / End of Cycle	200–300mg/week (0.5–0.75ml)	Gradual dose reduction across final 2–3 weeks; decanoate fraction maintains a residual serum baseline for several days after the last injection — factor into PCT timing

Key takeaways

Choose Suste-Testosterone 400mg when rapid androgenic onset and extended coverage are both required within a single injection.
Recognise that each ester fraction occupies a distinct release window, collectively spanning day one through day 21.
Expect 37.5% lower injection volume per dose compared to equivalent 250mg/ml multi-ester products.
Confirm injectable oil-depot delivery eliminates hepatic first-pass loss affecting oral testosterone forms.
Verify lot-specific HPLC and LAL documentation before administration to ensure ester proportions match label claims.

Ester Architecture: How Four Release Windows Operate in a Single Vial

Suste-Testosterone 400mg functions as a pharmacokinetic cascade: four testosterone esters with chemically distinct carbon-chain lengths occupy successive release windows so that serum testosterone remains elevated from the first day of injection through the second and third weeks without additional short-ester supplementation. Propionate — the shortest of the four — is hydrolysed by plasma esterases within 24–48 hours of injection, generating the earliest androgenic signal. Phenylpropionate extends that initial rise across days two through five, after which isocaproate takes over to bridge the mid-cycle period, and decanoate provides a slow, sustained baseline lasting up to 21 days. No single-ester compound replicates this coverage range: a user relying on testosterone enanthate alone must accept a 5–7 day delay before peak androgenic activity, whereas the propionate fraction in Suste-Testosterone eliminates that gap entirely.

Injectable Oil Depot vs. Other Delivery Forms: Why Esterification Matters

The intramuscular oil depot created by each injection acts as a diffusion-controlled reservoir. Esterified testosterone is pharmacologically inactive until plasma esterases cleave the ester bond, releasing free testosterone into circulation — a process whose rate is governed directly by ester chain length. This mechanism is fundamentally different from oral testosterone delivery (17-alpha-alkylated variants) or transdermal gels: injectable esters bypass hepatic first-pass metabolism entirely, producing systemic androgenic exposure that oral routes cannot match without liver-toxic modifications. Compared to transdermal testosterone, which delivers only 10–15% of applied dose to systemic circulation per published pharmacokinetic data, intramuscular esterified testosterone achieves near-complete bioavailability from the injection site depot. Beligas Pharmaceuticals formulates Suste-Testosterone 400mg in an oil-based vehicle specifically calibrated to maintain ester stability throughout the product's shelf life without precipitation at standard storage temperatures.

Concentration Differential: 400mg/ml vs. Standard 250mg/ml Blends

At 400mg/ml, Suste-Testosterone 400mg delivers a meaningfully higher testosterone mass per injection volume than conventional 250mg/ml multi-ester products. A user targeting 600mg per week draws 1.5ml of Suste-Testosterone 400mg compared to 2.4ml of a 250mg/ml equivalent — a 37.5% reduction in injected volume per administration. Reduced oil volume per injection decreases depot pressure at the injection site, which experienced users report as improved post-injection comfort. The 10ml vial format at 400mg/ml contains 4,000mg of total testosterone esters, supporting a 10-week cycle at 400mg/week from a single vessel. Each production lot undergoes HPLC verification to confirm that all four ester proportions meet their declared specification and that total testosterone concentration aligns with the 400mg/ml label claim — a dual-layer analytical confirmation rather than a single total-content check.

Usage

VERIFY ESTER INTEGRITY BEFORE FIRST USE: Inspect the vial against light for particulate matter or discolouration. Cross-reference the batch number against the accompanying certificate of analysis to confirm HPLC-verified ester proportions and LAL endotoxin clearance before drawing.
CALCULATE INJECTION VOLUME BASED ON 400mg/ml CONCENTRATION: At this concentration, 1.0ml = 400mg of testosterone esters. Use a 1ml or 2ml luer-lock syringe for accurate measurement — each 0.1ml graduation equals 40mg, enabling clean dose increments without estimation errors.
WARM THE VIAL FOR OPTIMAL VISCOSITY: High-concentration oil-based solutions are more viscous at room temperature. Hold the sealed vial in a closed fist or place briefly in warm (not hot) water for 30–60 seconds before drawing to reduce draw resistance and ensure complete dose extraction.
ROTATE INJECTION SITES SYSTEMATICALLY: Given the 400mg/ml concentration, depot oil volume per injection may generate localised pressure. Rotate between gluteus maximus, vastus lateralis, and deltoid (only for volumes under 1.0ml) on a structured schedule to allow full depot absorption before reinjection at the same site.
SYNCHRONISE INJECTION SCHEDULE WITH ESTER PHARMACOKINETICS: A Monday/Thursday split ensures the propionate fraction of Thursday's injection arrives while the isocaproate-to-decanoate tail of Monday's injection is still active — maintaining continuous serum testosterone coverage without a gap or excessive peak.
INITIATE BLOODWORK AT WEEK 4 TO ASSESS ESTER-SPECIFIC SERUM RESPONSE: Draw blood at mid-interval (approximately 3–4 days after the most recent injection) to capture a representative serum testosterone value reflecting the combined contribution of all four active ester fractions rather than a propionate-driven peak or a decanoate trough.

Warnings

Contraindications: Suste-Testosterone 400mg is contraindicated in individuals with confirmed or suspected androgen-dependent tumours including prostate carcinoma, in patients with pre-existing polycythaemia vera, severe cardiac insufficiency, or uncontrolled hypertension. This formulation is not appropriate for paediatric use or for women who are pregnant or may become pregnant. Users with documented sensitivity to the excipient oil carrier should verify the specific vehicle composition with Beligas Pharmaceuticals before administration.

Side_Effects: Conversion of elevated exogenous testosterone to estradiol via aromatase activity presents the primary estrogenic risk at doses exceeding 400mg/week — manifesting as fluid accumulation, breast tissue sensitivity, and progressive blood pressure increase. The long-acting decanoate fraction prolongs androgenic exposure beyond the injection interval, meaning scalp sensitivity, sebaceous activity, and acne can persist for up to three weeks after the final dose. Dose-dependent increases in red blood cell mass represent a cardiovascular risk that requires active haematological surveillance. Suppression of the hypothalamic-pituitary-gonadal axis is an expected pharmacological consequence of all exogenous testosterone use and is not ester-specific.

Monitoring: Establish baseline values for haematocrit, serum PSA, hepatic transaminases, and fasting lipid panel before the first injection. Repeat haematocrit and PSA at six-week intervals throughout the cycle. Serum estradiol should be measured at cycle week 4 and adjusted against aromatase inhibitor dosing if the value exceeds 40 pg/mL. A blood draw timed 72–96 hours after the preceding injection captures the most representative steady-state testosterone concentration across this product's multi-ester kinetic profile. Lipid reassessment at cycle week 8 is the minimum standard for cardiovascular risk management.

PCT: The decanoate component of Suste-Testosterone 400mg sustains measurable serum testosterone concentrations for 18–21 days after the final injection, during which time SERM-based recovery therapy cannot meaningfully stimulate gonadotrophin release against prevailing androgenic suppression. PCT should therefore not begin before day 18–21 post-last dose. Tamoxifen and clomiphene — used individually or in combination — are the established recovery agents once the washout threshold is crossed. Gonadotrophin recovery should be confirmed by sequential LH, FSH, and total testosterone measurements at PCT weeks 2, 4, and 6.

Frequently asked questions

What is the pharmacokinetic difference between the four esters in Suste-Testosterone 400mg?: Each ester has a distinct carbon-chain length that determines how quickly plasma esterases cleave it: propionate activates within 24–48 hours, phenylpropionate peaks around days 2–5, isocaproate sustains activity through day 8–12, and decanoate provides a residual androgenic baseline up to 18–21 days post-injection. Together they create a seamless release cascade that no single ester can replicate alone.
How does injectable testosterone ester delivery compare to oral or transdermal forms?: Injectable esterified testosterone achieves near-complete systemic bioavailability because the intramuscular depot bypasses hepatic first-pass metabolism entirely. Transdermal testosterone delivers only 10–15% of the applied dose to systemic circulation according to published pharmacokinetic data. Oral testosterone variants require 17-alpha-alkylation for absorption, which introduces hepatotoxic liability that esterified injectables like Suste-Testosterone 400mg do not carry.
Which ester fraction within Suste-Testosterone 400mg is most useful for athletes who want rapid androgenic onset?: The propionate fraction is responsible for rapid onset — it is hydrolysed within the first 24–48 hours and generates the earliest measurable serum testosterone elevation. This makes the blend suitable for athletes who cannot tolerate the 5–7 day lag associated with long-ester-only products like testosterone enanthate or cypionate, while the remaining three esters maintain androgenic activity through the weeks that follow.
Why does Suste-Testosterone 400mg draw a smaller injection volume than 250mg/ml blends at the same weekly dose?: At 400mg/ml, each millilitre contains 60% more active testosterone esters than a 250mg/ml formulation. A 600mg weekly dose requires only 1.5ml of Suste-Testosterone 400mg versus 2.4ml of a 250mg/ml product — a 37.5% volume reduction per administration. Smaller oil depot volume per injection lowers depot pressure at the injection site, which users typically associate with reduced post-injection discomfort.
How should the 10ml vial of Suste-Testosterone 400mg be stored and handled after the first draw?: Store the vial at controlled room temperature (15–25°C), away from direct light and moisture. After the first needle puncture of the rubber septum, maintain aseptic technique — use a new sterile needle for every draw. The vial does not require refrigeration after opening, but should not be exposed to temperatures above 30°C. Inspect the solution visually before each draw; discard the vial if particulate matter or cloudiness is observed. (2) angle_used

Manufacturer

Beligas Pharmaceuticals holds a well-established position in the pharmaceutical-grade performance market, built on a reputation anchored to two measurable outcomes: consistent potency verification across its injectable portfolio and transparent lot-level documentation accessible to end users. Within the concentrated injectable segment — where Suste-Testosterone 400mg sits — market standing is determined not by brand claims alone, but by the reproducibility of analytical results across sequential production batches. Beligas reinforces this position by operating within a framework where HPLC potency data and LAL endotoxin results accompany each lot, enabling distributors and users alike to validate the product against its label specification rather than relying solely on the manufacturer's assurance. The brand's market credibility in this specific product category is further supported by its track record across a broad injectable range: consistent manufacturing standards applied to testosterone esters, trenbolone variants, and ancillary compounds demonstrate that quality controls are structural to the production process rather than selectively applied. Suste-Testosterone 400mg is positioned as the flagship high-concentration multi-ester offering within Beligas' testosterone line — a product that reflects both the brand's technical capability in solvent-system optimisation at elevated concentrations and its commercial decision to make verified pharmaceutical-grade testosterone accessible at a price point competitive within the performance market.

Product details

Brand	Beligas Pharmaceuticals
Active ingredient	testosterone mix
Also known as	Sustanon, Omnadren, Testosterone-Mischung, Sustanon 250, Suste-Testosteronee 400mg, Beligas Pharmaceuticals Sustanon
Strength	400 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TMIX-BEL-400-003

Reviews

5/5

2 reviews

Rating: 5 out of 5 starsCharlie M.Verified purchaseAug 1, 2026
best test blend out there
Pinning 800mg a week on a 14-week bulk. bloodwork at week 6 showed test at 3,200 ng/dl, hematocrit sittign at 47% which is fine. Put on 8kg total, kept water manageable with aromasin. PIP is basically zero, oil flows through a 23g with no drama. Discrete parcel, no issues with shipping whatsoever. Absolutely class product
Rating: 5 out of 5 starshydra47Verified purchaseJun 21, 2026
Dialled in all cycle
Used this at 600mg weekly alongside 300mg deca for 16 weeks. Appetite went mental by week 3, joints felt great, libido stayed high the entire run, finished the cycle at 98kg from 89kg, kept most of it after PCT. Bloodwork looked clean, lipids only shifted slightly. Shipping was fast and packaged properly. Will def be ordering again next cycle.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Sustandrol 250mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

GMP Standard

Sustandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Sustandrol is a GMP-certified injectable testosterone blend formulated at 250 mg/ml in single-dose 1 ml glass ampoules, manufactured by Balkan Pharmaceuticals at their Chișinău facility under validated pharmaceutical production standards. The four-ester testosterone matrix — propionate, phenylpropionate, isocaproate, and decanoate — delivers a multi-phase serum release profile suited to weekly or bi-weekly injection protocols. Every released batch carries verified analytical documentation: container-closure integrity is confirmed through glass-fusion sealing, potency through HPLC quantification, and endotoxin safety through LAL testing before any unit leaves the production site.

€42.00

High Concentration

Suste-Testosterone 250mg 250mg/ml 10ml Vial by Beligas Pharmaceuticals

Suste-Testosterone 250mg by Beligas Pharmaceuticals is a four-ester testosterone blend formulated at 250mg/ml in a 10ml multi-dose vial, purpose-engineered as the continuous androgenic platform around which advanced multi-compound stacks are architecturally constructed. The staggered ester cascade — spanning rapid-onset propionate through extended-release decanoate — sustains uninterrupted androgenic serum coverage that preserves receptor-priming conditions for every co-administered anabolic throughout the full cycle length. Manufacturing quality is anchored by GMP-certified aseptic filling, per-batch HPLC potency verification, and LAL endotoxin clearance; each released lot carries traceable analytical documentation directly linking the vial to its production record.

€39.00

Susten-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Top Seller

Susten-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Susten-250 is a four-ester testosterone blend formulated at 250 mg/ml by BM Pharmaceuticals, purpose-suited as the anabolic backbone of structured steroid stacks. Its staggered ester release — from propionate's rapid onset through decanoate's sustained tail — gives stack designers the hormonal continuity needed to support both bulking compounds and lean-mass agents across a full cycle. Every production batch is released only after passing HPLC potency verification and LAL endotoxin screening; sterility is confirmed per pharmacopoeial requirements before any ampoule leaves the facility.

€42.00

Testobolin-400 400mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Original Product

Testobolin-400 400mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testobolin-400 is a four-ester injectable testosterone preparation concentrated at 400 mg/ml by BM Pharmaceuticals, engineered to deliver a pharmacokinetically broad androgenic profile that no single-ester compound can replicate within one administration event. The staggered ester architecture progresses from rapid-onset propionate through to long-depot decanoate, spanning multiple half-life windows simultaneously and eliminating the frequency-versus-stability trade-off that constrains propionate-only or enanthate-only protocols. Each production lot is cleared through ester-resolved HPLC potency verification and LAL endotoxin assay, with lot-traceable Certificates of Analysis issued before any ampoule enters distribution.

€47.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00